var data={"title":"Ertapenem: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ertapenem: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6127?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ertapenem-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ertapenem: Patient drug information&quot;</a> and <a href=\"topic.htm?path=ertapenem-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ertapenem: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166533\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>INVanz</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166534\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Invanz</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166557\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Carbapenem</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166537\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> IV therapy may be administered for up to 14 days; IM for up to 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Community-acquired pneumonia and complicated urinary tract infections (including pyelonephritis):</b> IM, IV: 1 g once daily; duration of total antibiotic treatment: 10 to 14 days; duration includes possible switch to appropriate oral therapy after at least 3 days of parenteral treatment, once clinical improvement demonstrated. <b>Note:</b> The carbapenems, including ertapenem, are preferred agents for <i>Enterobacter</i> spp and  <i>Burkholderia pseudomallei,</i> and are considered alternative agents for anaerobes in aspiration pneumonia (IDSA 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-abdominal infection:</b> IM, IV: 1 g once daily for 5 to 14 days; <b>Note:</b> 2010 IDSA guidelines recommend a treatment duration of 4 to 7 days (provided source controlled) for community-acquired, mild to moderate intra-abdominal infections (Solomkin 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteomyelitis, native vertebral due to </b>\n      <b>Enterobacteriaceae </b>\n      <b>(off-label use): </b>IV<b>:</b> 1 g once daily for 6 weeks (IDSA [Berbari 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pelvic infections (acute):</b> IM, IV: 1 g once daily for 3-10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis of surgical site following colorectal surgery:</b> IV: 1 g as a single dose given 1 hour preoperatively</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin structure infections (excluding diabetic foot infections with osteomyelitis):</b> IM, IV: 1 g once daily for 7 to 14 days. <b>Notes:</b>  For diabetic foot infections, recommended treatment duration is up to 4 weeks depending on severity of infection and response to therapy (Lipsky 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intravenous catheter-related bloodstream infection (off-label use): </b> IV 1 g once daily (<b>Note:</b> Carbapenems, including ertapenem, are preferred agents for extended-spectrum &beta;-lactamase [ESBL]-positive <i>Escherichia coli</i> and <i>Klebsiella, Enterobacter, </i> and <i>Serratia</i> [IDSA, 2009].)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prosthetic joint infection: <b><i>Enterobacter</i></b> spp (off-label use)</b>: IV: 1 g every 24 hours for 4 to 6 weeks (Osmon 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and soft tissue necrotizing infections (off-label use):</b> IV: 1 g once daily in combination with an agent effective against MRSA (eg, vancomycin, linezolid, daptomycin) for empiric therapy of polymicrobial (mixed) infections. Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (IDSA [Stevens 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical site infection (intestinal or genitourinary tract surgery) (off-label use):</b> IV: 1 g once daily (IDSA [Stevens, 2014]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166549\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=ertapenem-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ertapenem: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">\n      <b>Note:</b> IV therapy may be administered for up to 14 days; IM therapy for up to 7 days</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:2em;text-align:justify;\">Infants &ge;3 months and Children: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">\n      <b>Community-acquired pneumonia and complicated urinary tract infections (including pyelonephritis):</b> IM, IV: 15 <b>mg</b>/kg twice daily (maximum: 1 g daily); duration of total antibiotic treatment: 10-14 days (<b>Note:</b> Duration includes possible switch to appropriate oral therapy after at least 3 days of parenteral treatment, once clinical improvement demonstrated.)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">\n      <b>Intra-abdominal infection:</b> IM, IV: 15 <b>mg</b>/kg twice daily (maximum: 1 g daily) for 5-14 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">\n      <b>Pelvic infections (acute):</b> IM, IV: 15 <b>mg</b>/kg twice daily (maximum: 1 g daily) for 3-10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">\n      <b>Skin and skin structure infections:</b> IM, IV: 15 <b>mg</b>/kg twice daily (maximum: 1 g daily) for 7-14 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">\n      <b>Skin and soft tissue necrotizing infections (off-label use):</b> IV: 15 mg/kg every 12 hours in combination with an agent effective against MRSA (eg, vancomycin, linezolid, daptomycin) for empiric therapy of polymicrobial (mixed) infections. Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (IDSA [Stevens, 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <b>Community-acquired pneumonia, complicated urinary tract infections (including pyelonephritis):</b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infection:</b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pelvic infections (acute):</b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and skin structure infections (excluding diabetic foot infections with osteomyelitis):</b> Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166538\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166539\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children: No data available for pediatric patients with renal insufficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">CrCl &gt;30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">CrCl &le;30 mL/minute/1.73 m<sup>2</sup> and ESRD: 500 mg/day </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: When the daily dose is given within 6 hours prior to hemodialysis, a supplementary dose of 150 mg is required following hemodialysis. If ertapenem is given at least 6 hours prior to hemodialysis, no supplementary dose is needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">CAPD: IV: 500 mg daily (Cardone, 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166540\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Adjustments cannot be recommended (lack of experience and research in this patient population).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166510\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">INVanz: 1 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">INVanz: 1 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166496\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166512\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IM: Avoid injection into a blood vessel. Make sure patient does not have an allergy to lidocaine or another anesthetic of the amide type. Administer by deep IM injection into a large muscle mass (eg, gluteal muscle or lateral part of the thigh). Do not administer IM preparation or drug reconstituted for IM administration intravenously. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: Infuse over 30 minutes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166511\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Moderate-to-severe infections:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute pelvic infections:</b>  For the treatment of acute pelvic infections, including postpartum endomyometritis, septic abortion, and postsurgical gynecologic infections caused by <i>Streptococcus agalactiae</i>, <i>Escherichia coli</i>, <i>Bacteroides fragilis</i>, <i>Porphyromonas asaccharolytica</i>, <i>Peptostreptococcus</i> spp, or <i>Prevotella bivia</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Community-acquired pneumonia:</b> For the treatment of community-acquired pneumonia (CAP) caused by <i>Streptococcus pneumoniae</i> (penicillin-susceptible isolates only), including cases with concurrent bacteremia; <i>Haemophilus influenzae</i> (beta-lactamase-negative isolates only); or <i>Moraxella catarrhalis</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Complicated intra-abdominal infections: </b>For the treatment of complicated intra-abdominal infections caused by <i>E. coli</i>, <i>Clostridium clostridioforme</i>, <i>Eubacterium lentum</i>, <i>Peptostreptococcus</i> spp, <i>B. fragilis</i>, <i>Bacteroides distasonis</i>, <i>Bacteroides ovatus</i>, <i>Bacteroides thetaiotaomicron</i>, or <i>Bacteroides uniformis</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Complicated skin and skin structure infections:</b> For the treatment of complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis caused by <i>Staphylococcus aureus</i> (methicillin-susceptible isolates only), <i>S. agalactiae</i>, <i>Streptococcus pyogenes</i>, <i>E. coli</i>, <i>Klebsiella pneumoniae</i>, <i>Proteus mirabilis</i>, <i>B. fragilis</i>, <i>Peptostreptococcus</i> spp, <i>P. asaccharolytica</i>, or <i>P. bivia</i>. Ertapenem has not been studied in diabetic foot infections with concomitant osteomyelitis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Complicated urinary tract infections:</b> For the treatment of complicated urinary tract infections (UTIs), including pyelonephritis caused by <i>E. coli</i>, including cases with concurrent bacteremia or <i>K. pneumoniae</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis of surgical-site infection in colorectal surgery:</b> For the prophylaxis of surgical-site infection in adults following elective colorectal surgery.</p>\n    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">\n      <b>Note:</b> Methicillin-resistant <i>Staphylococcus aureus, Enterococcus</i> spp, penicillin-resistant strains of <i>Streptococcus pneumoniae</i> , <i>Acinetobacter</i>, and <i>Pseudomonas aeruginosa</i>,  are <b>resistant</b> to ertapenem while most extended-spectrum beta-lactamase (ESBL)-producing bacteria remain sensitive to ertapenem.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25473714\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Intravascular catheter-associated bloodstream infection; Osteomyelitis, native vertebral; Prosthetic joint infection; Skin and soft tissue necrotizing infections; Surgical Site Infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166564\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ertapenem may be confused with doripenem, imipenem, meropenem</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">INVanz may be confused with AVINza, IV vancomycin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166502\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%: Gastrointestinal: Diarrhea (6% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Edema (3%), chest pain (&lt;2%), phlebitis (&lt;2%), thrombophlebitis (&lt;2%), hypotension (1% to 2%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache (2% to 7%), altered mental status (eg, agitation, confusion, disorientation, mental acuity decreased, somnolence, stupor) (3% to 5%), insomnia (3%), dizziness (2%), hypothermia (infants, children, and adolescents &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Diaper rash (infants and children 5%), skin rash (2% to 3%), pruritus (1% to 2%), genital rash (infants, children, and adolescents &lt;2%), skin lesion (infants, children, and adolescents &lt;2%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Vomiting (2% to 10%), nausea (6% to 9%), abdominal pain (4% to 5%), constipation (2% to 4%), decreased appetite (infants, children, and adolescents &lt;2%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Erythrocyturia (1% to 3%), vaginitis (1% to 3%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Thrombocythemia (4% to 7%), decreased neutrophils (3% to 6%), decreased hemoglobin (5%), decreased hematocrit (3%), leukocyturia (2% to 3%), leukopenia (&lt;2%), eosinophilia (1% to 2%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Increased serum ALT (8% to 9%), increased serum AST (7% to 8%), increased serum alkaline (4% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Herpes simplex infection (infants, children, and adolescents &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Infused vein complication (4% to 7%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia (infants, children, and adolescents &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Otic: Otic infection (infants, children, and adolescents &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Cough (&le;4%), dyspnea (1% to 3%), nasopharyngitis (infants, children, and adolescents &lt;2%), rhinitis (infants, children, and adolescents &lt;2%), rhinorrhea (infants, children, and adolescents &lt;2%), upper respiratory tract infection (infants, children, and adolescents 2%), wheezing (infants, children, and adolescents &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever (2% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Abdominal distention, acid regurgitation, aggressive behavior, anaphylactoid reaction, anaphylaxis, anorexia, anuria, anxiety, asthma, asystole, ataxia, atrial fibrillation, bladder dysfunction, bradycardia, bronchoconstriction, cardiac arrest, cardiac arrhythmia, cardiac failure, chills, cholelithiasis, <i>Clostridium difficile</i> associated diarrhea, decreased serum albumin, dehydration, delirium, dental discoloration, depression, dermatitis, desquamation, diaphoresis, DRESS syndrome, duodenitis, dysgeusia, dyskinesia, dyspepsia, dysphagia, epistaxis, erythema, esophagitis, extravasation, facial edema, fatigue, flank pain, flatulence, flushing, gastritis, gastrointestinal hemorrhage, gout, hallucination, heart murmur, hematoma, hemoptysis, hemorrhoids, hiccups, hyperglycemia, hyperkalemia, hypertension, hypoesthesia, hypokalemia, hypoxemia, impaired consciousness, increased blood urea nitrogen, increased serum bilirubin (total), increased serum creatinine, increased serum sodium, induration at injection site, intestinal obstruction, jaundice, leg pain, malaise, muscle spasm, myoclonus, nervousness, oliguria, oral candidiasis, oral mucosa ulcer, pain, pain at injection site, pancreatitis, paresthesia, pharyngitis, pleural effusion, pleuritic chest pain, prolonged prothrombin time, pyloric stenosis, rales, renal insufficiency, respiratory distress, rhonchi, seizure, septicemia, septic shock, sore throat, stomatitis, subdural hematoma, syncope, tachycardia, thrombocytopenia, tissue necrosis, tremor, unsteady gait, urinary retention, urticaria, ventricular tachycardia, vertigo, voice disorder, vulvovaginal candidiasis, vulvovaginal pruritus, vulvovaginitis, weakness, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\"></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166515\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams; known hypersensitivity to local anesthetics of the amide type due to the use of lidocaine as a diluent (IM use only).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166500\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylaxis/hypersensitivity reactions: Serious hypersensitivity reactions, including anaphylaxis, have been reported (some without a history of previous allergic reactions to beta-lactams).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS effects: Carbapenems have been associated with CNS adverse effects, including confusional states and seizures (myoclonic); use caution with CNS disorders (eg, brain lesions and history of seizures) and adjust dose in renal impairment to avoid drug accumulation, which may increase seizure risk. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required in patients with moderate-to-severe renal dysfunction. Increased seizure risk has been reported in patients with renal dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Valproic acid and derivatives:  Carbapenems, including ertapenem, may decrease the serum concentration of divalproex sodium/valproic acid increasing the risk of breakthrough seizures. Concurrent use of carbapenem antibiotics with divalproex sodium/valproic acid is generally not recommended. Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional antiseizure medication. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Lower doses (based upon renal function) are often required in the elderly. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\"> &bull; IM administration: Doses for IM administration are mixed with lidocaine; consult Lidocaine (Systemic) information for associated Warnings/Precautions. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299280\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166504\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8675&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Ertapenem.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Ertapenem may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: Carbapenems may decrease the serum concentration of Valproate Products.  Management: Concurrent use of carbapenem antibiotics with valproic acid is generally not recommended.  Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166506\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166516\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Teratogenic effects were not observed in animal reproduction studies. Ertapenem is approved for the treatment of postpartum endomyometritis, septic abortion, and postsurgical infections. Information related to use during pregnancy has not been located. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166517\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Ertapenem is excreted in breast milk. The low concentrations in milk and low oral bioavailability suggest minimal exposure risk to the infant. The manufacturer recommends that caution be exercised when administering ertapenem to nursing women. Nondose-related effects could include modification of bowel flora.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166518\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166508\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Periodic renal, hepatic, and hematopoietic assessment during prolonged therapy; neurological assessment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166499\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins; which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166514\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: IM: Almost complete</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &ge;3 months and Children: ~0.2 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents 13 to 17 years: ~0.16 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: ~0.12 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding (concentration dependent, primarily to albumin): 85% at 300 mcg/mL, 95% at &lt;100 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Non-CYP-mediated hydrolysis to inactive metabolite</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: IM: ~90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &ge;3 months and Children: ~2.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents and Adults: ~4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: IM: ~2.3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~80% as unchanged drug and metabolite); feces (~10%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323133\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (INVanz Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $154.39</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (INVanz Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $162.10</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2869380\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Etropen (BD);</li>\n      <li>Invanz (AE, AR, AT, AU, BB, BE, BG, BH, BO, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IN, IS, IT, JO, KR, LB, LK, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PR, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TW, UA, UY, VE, VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Berbari EF, Kanj SS, Kowalski TJ, et al; Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. <i>Clin Infect Dis</i>. 2015;61(6):e26-e46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/26229122/pubmed\" target=\"_blank\" id=\"26229122\">26229122</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo; <i>Am J Health Syst Pharm</i>, 2013, 70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cardone KE, Grabe DW, Kulawy RW, et al, &ldquo;Ertapenem Pharmacokinetics and Pharmacodynamics During Continuous Ambulatory Peritoneal Dialysis,&rdquo; <i>Antimicrob Agents Chemother</i>, 2011, 56(2):725-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/22083473/pubmed\" target=\"_blank\" id=\"22083473\">22083473</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Invanz (ertapenem) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co, Inc; June 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Invanz (ertapenem) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipsky BA, Berendt AR, Cornia PB, et al, &quot;2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,&quot; <i>Clin Infect Dis</i>, 2012, 54(12):e132-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/22619242/pubmed\" target=\"_blank\" id=\"22619242\">22619242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lunde JL, Nelson RE, and Storandt HF, &ldquo;Acute Seizures in a Patient Receiving Divalproex Sodium After Starting Ertapenem Therapy,&rdquo; <i>Pharmacotherapy</i>, 2007, 27(8):1202-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/17655519/pubmed\" target=\"_blank\" id=\"17655519\">17655519</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mandell LA, Wunderink RG, Anzueto A, et al, &ldquo;Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults,&rdquo; 2007, <i>Clin Infect Dis</i>, 44(Suppl 2):27-72<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/17278083/pubmed\" target=\"_blank\" id=\"17278083\">17278083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mermel LA, Allon M, Bouza E, et al, &ldquo;Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2009, 49(1):1-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/19489710/pubmed\" target=\"_blank\" id=\"19489710\">19489710</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2013, 56(1):e1-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/23223583/pubmed\" target=\"_blank\" id=\"23223583\">23223583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seto AH, Song JC, and Guest SS, &ldquo;Ertapenem-Associated Seizures in a Peritoneal Dialysis Patient,&rdquo; <i>Ann Pharmacother </i>, 2005, 39(2):352-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/15644469/pubmed\" target=\"_blank\" id=\"15644469\">15644469</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2010, 50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ertapenem-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8675 Version 126.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F166533\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F166534\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F166557\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F166537\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F166549\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F166538\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F166539\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F166540\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F166510\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F166496\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F166512\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F166511\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25473714\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F166564\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F166502\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F166515\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F166500\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299280\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F166504\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F166506\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F166516\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F166517\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F166518\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F166508\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F166499\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F166514\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323133\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F2869380\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8675|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ertapenem-patient-drug-information\" class=\"drug drug_patient\">Ertapenem: Patient drug information</a></li><li><a href=\"topic.htm?path=ertapenem-pediatric-drug-information\" class=\"drug drug_pediatric\">Ertapenem: Pediatric drug information</a></li></ul></div></div>","javascript":null}